Northland Securities analyst Carl Byrnes maintained a Buy rating on Motif Bio plc (MTFB) today and set a price target of $5. The company’s shares closed on Friday at $2.23, close to its 52-week low of $1.54.
Byrnes noted:
“We anticipate minutes from the Type A meeting in early-June, and remain cautiously optimistic that iclaprim will have a regulatory path forward.”
According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -6.9% and a 17.6% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Motif Bio plc with a $3.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.45 and a one-year low of $1.54. Currently, Motif Bio plc has an average volume of 733.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motif Bio Plc is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi).
